SLC4A1 · Western blot design guide

SLC4A1 Western Blot Planning Guide

Plan a SLC4A1 Western blot around the catalog-observed 101.8 kDa band, image-backed M01146-1 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for SLC4A1 (SLC4A1): expected band 101.8 kDa, antibody M01146-1, and guide-derived SDS-PAGE protocol steps
SLC4A1 Western blot protocol sheet — expected band 101.8 kDa, antibody M01146-1, controls and PMC citations. Open the full SLC4A1 WB guide →

SLC4A1 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 101.8 kDa
Observed band Not reported — verify product WB image
Gel 8-10%
Positive control ⓘ Kidney
Negative control ⓘ Adrenal gland
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 101.8 kDa
ⓘ Localization Cell membrane / Basolateral cell membrane
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated SLC4A1 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateKidney
Gel %8-10%
Load20-30 µg total protein per lane
TransferWet/tank, extended transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryM01146-1 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected SLC4A1 Western Blot Band Size?

Use the product-observed 101.8 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
101.8 kDaMatches the authoritative product WB observation.
101.8 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected SLC4A1 appearancePlan around 101.8 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band101.8 kDa; use this as the primary experimental expectation.
Calculated mass101.8 kDa from UniProt P02730; retain as context.
Gel selection8-10%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with M01146-1.
Why is my band missing or off?
SituationLikely causeNext action
101.8 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for SLC4A1 Western blot

🧪Use Kidney as the first positive-control candidate and Adrenal gland as the HPA Not detected negative candidate.
Positive control: Kidney (Medium)
Negative control: Adrenal gland (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for SLC4A1

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Kidney Reported tissue cells Medium Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Adrenal gland Reported tissue cells Not detected Protein (HPA) HPA →
Appendix Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced SLC4A1 Western Blot Tips

Deeper troubleshooting and optimisation questions for SLC4A1, answered from its protein features.

Which band should guide the blot?
Use 101.8 kDa, the observation attached to the authoritative M01146-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 101.8 kDa expectation.
Which positive control should I start with?
Start with Kidney, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adrenal gland as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for SLC4A1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should M01146-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

SLC4A1 Western Blot Reagents

Human/Mouse/Rat-reactive SLC4A1 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for SLC4A1 using M01146-1; observed band 101.8 kDa
Anti-SLC4A1/CD233/Band 3 Antibody Picoband® (monoclonal, 5G2G7)
Cat # M01146-1
Real WB data Western blot validation image for SLC4A1 using PB9437; observed band 101.8 kDa
Anti-SLC4A1/CD233/Band 3 Antibody Picoband®
Cat # PB9437

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P02730
  2. Human Protein Atlas — SLC4A1
  3. M01146-1 product record
  4. PMC10870408 — Phage Display Screening of Anchor Peptides for Red Blood Cell-Derived Extracellular Vesicles (ACS omega, 2024)
  5. PMC8106864 — DIA proteomics analysis through serum profiles reveals the significant proteins as candidate biomarkers in women with PCOS (BMC medical genomics, 2021)